Kallyope becomes TriGemX, raises $94M for migraine therapy: Venture Report

Kallyope’s rebrand to migraine company TriGemX and $94 million cash infusion are intended to support the company through pivotal testing.

After selling its obesity programs to Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO), Kallyope Inc. is becoming TriGemX Bio Inc. as it advances TRPM8 channel blocker elismetrep (K-304) through Phase III testing for the acute migraine treatment...